An initial investment of $5 billion, collectively referred to as Project NextGen, will accelerate and streamline the rapid development of the next generation of vaccines and treatments through public-private collaborations.
Based at the U.S. Department of Health and Human Services (HHS) and led by ASPR’s Biomedical Advanced Research and Development Authority (BARDA) and the National Institutes of Health (NIH’s) National Institute of Allergy and Infectious Diseases (NIAID), Project NextGen will coordinate across the federal government and the private sector to advance the pipeline of new, innovative vaccines and therapeutics into clinical trials and potential review by the U.S. Food and Drug Administration (FDA) for authorization or approval, and commercial availability for the American people.
Read the full fact sheet from ASPR online.